A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies

Overview

About this study

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of PT01 administered intravenously in subjects with advanced malignancies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Able to understand and voluntarily sign an informed consent form (ICF).
  • Male and female adults ≥ 18 years of age at the time of informed consent 
  • Advanced solid malignancies for which no standard therapy is available. Subjects in whom available standard therapy is contraindicated may be eligible. 

For Dose Expansion Phase - Expansion Group A:

  • Histologically confirmed unresectable locally advanced or metastatic (AJCC stage IIIB, IIIC, or IV) cutaneous malignant melanoma for which no standard therapy is suitable. 
  • At least 1 measurable site of disease as defined per RECIST v1.1 criteria (Dose Expansion Phase) or evaluable disease (Dose Escalation Phase only).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
  • Life expectancy of > 12 weeks.
  • Adequate hematologic status within 28 days prior to dosing as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: 
    • Absolute neutrophil count (ANC) ≥1.5 × 10^9/L;
    • Platelet count ≥ 100 × 10^9/L;
    • Hemoglobin ≥ 90 g/L.
  • Adequate liver function as demonstrated by:
    • Serum bilirubin < 2 × the upper limit of normal (ULN);
    • Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN or ≤ 5 × ULN in subjects with liver metastases;
    • Gamma-glutamyl transferase ≤ 5 × ULN;
    • Alkaline phosphatase ≤ 3 × ULN or ≤ 5 × ULN if bone or liver metastasis is present.
  • Serum creatinine ≤ 1.5 × ULN or estimated creatinine clearance ≥ 50 mL/min according to the Cockcroft-Gault formula.
  • Prothrombin time (PT) (or International Normalized Ratio [INR]) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN or within the intended therapeutic range within 72 hours before the first dose of study drug in subjects receiving anticoagulant therapy.
  • Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.
  • Absence of any other malignancy which has been active or treated within the past 3 years, except for cervical intraepithelial neoplasia, and nonmelanoma skin cancers (basal cell and squamous cell carcinomas).
  • Men who are sterile (including vasectomy confirmed by post vasectomy semen analysis) OR agree to use a condom with spermicide and to not donate sperm during the study and for at least 90 days following last dose of PT01.
  • Female subjects must be postmenopausal (> 12 months without menses) or surgically sterile (i.e., by hysterectomy and/or bilateral oophorectomy) or must be using highly effective contraception (i.e., oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 90 days after their last dose of PT01.
  • Subjects who are of childbearing potential must have a negative serum pregnancy test at Screening and within 72 hours prior to the first dose.
  • Peripheral forearm veins suitable for venous access including cannulation for infusion of PT01 and multiple blood sampling.

Exclusion Criteria:

  • Received prior arginase or arginine deiminase therapy.
  • Received recent anticancer therapy defined by: 
    • Chemotherapy, immunotherapy, hormonal therapy, and monoclonal antibodies (but excluding nitrosourea, mitomycin-C, targeted therapy) ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy to Grade≤1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v4.03) except for subjects with alopecia; subjects receiving luteinizing hormone-releasing hormone agonists may be considered for enrollment after discussion with the Sponsor;
    • Last administration of nitrosourea or mitomycin-C ≤ 42 days prior to starting study drug or who have not recovered from the side effects of such therapy to Grade ≤ 1;
    • Targeted therapy (e.g., sunitinib, sorafenib, pazopanib) ≤ 14 days prior to starting study drug, or who have not recovered from the side effects of such therapy to Grade ≤ 1; 
    • Radiotherapy ≤ 28 days prior to starting study drug or ≤ 14 days prior to starting study drug in the case of localized radiotherapy (e.g., for analgesic purpose or for lytic lesions at risk of fracture) or who have not recovered from radiotherapy toxicities to Grade ≤ 1.
  • Undergone major surgery (e.g., intrathoracic, intraabdominal, or intrapelvic), open biopsy, or significant traumatic injury ≤ 28 days prior to starting study treatment; subjects who have had minor procedures, percutaneous biopsies, or placement of vascular access device ≤ 7 days prior to starting study drug; or subjects who have not recovered from side effects of such procedure or injury.
  • Uncontrolled concurrent illness including, but not limited to, ongoing or active serious infection requiring systemic antimicrobials (within 14 days prior to first dose), uncontrolled arterial hypertension (> 160/100 mm Hg on antihypertensive medications), chronic pulmonary disease requiring oxygen, known bleeding disorders, uncontrolled endocrine diseases, altered mental status, or psychiatric illness/social situations that would limit compliance with protocol requirements.
  • Significant cardiac or pulmonary disease defined by New York Heart Association Class III or IV, history of myocardial infarction within 6 months prior starting study drug, significant unstable arrhythmia, or evidence of ischemia on ECG.
  • Symptomatic or uncontrolled brain metastases requiring current treatment (fewer than 28 days from last cranial radiation or from last steroids use).
  • Healing or open wound(s).
  • Lack of recovery of prior AEs to Grade ≤ 1 severity (except alopecia or lymphopenia) due to medications administered prior to the first dose of study drug.
  • Any other condition or finding (including social situation) that, in the opinion of the Investigator, may render the subject to be either at excessive risk for treatment complications or not able to provide evaluable outcome information.
  • Pregnant or breast-feeding women.
  • Known allergy to any of the formulation components of PT01.

Eligibility last updated 2/11/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Yujie Zhao, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Wen Wee Ma, M.B.B.S.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Cassandra Moore, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20477453

Mayo Clinic Footer